Elisa Genuardi
Overview
Explore the profile of Elisa Genuardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Matera A, Marella A, Maeda A, Da Via M, Lazzaroni F, Fabris S, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555330
Multiple myeloma (MM) has a highly heterogeneous genetic background, which complicates its molecular tracking over time. Nevertheless, each MM patient's malignant plasma cells (PCs) share unique V(D)J rearranged sequences at...
12.
Ferrero S, Grimaldi D, Genuardi E, Drandi D, Zaccaria G, Alessandria B, et al.
Blood
. 2022 Jun;
140(12):1378-1389.
PMID: 35737911
Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial...
13.
Genuardi E, Alessandria B, Civita A, Ferrero S
Methods Mol Biol
. 2022 May;
2453:119-132.
PMID: 35622324
Although MRD monitoring by the classic polymerase chain reaction (PCR) approach is a powerful outcome predictor, about 20% of mantle cell lymphoma (MCL) and 50% of follicular lymphoma (FL) patients...
14.
Zaccaria G, Ferrero S, Hoster E, Passera R, Evangelista A, Genuardi E, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008361
Background: Multicenter clinical trials are producing growing amounts of clinical data. Machine Learning (ML) might facilitate the discovery of novel tools for prognostication and disease-stratification. Taking advantage of a systematic...
15.
Mantoan B, Genuardi E, Ferrante M, Della Starza I, Ciabatti E, Grassi S, et al.
Hemasphere
. 2021 Sep;
5(10):e639.
PMID: 34514343
No abstract available.
16.
Stewart J, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G, et al.
Blood Adv
. 2021 Aug;
5(16):3188-3198.
PMID: 34424321
Current diagnostic standards for lymphoproliferative disorders include multiple tests for detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements, translocations, copy-number alterations (CNAs), and somatic mutations. The EuroClonality-NGS DNA...
17.
Genuardi E, Romano G, Beccuti M, Alessandria B, Mannina D, Califano C, et al.
Br J Haematol
. 2021 May;
194(2):378-381.
PMID: 34002365
Minimal residual disease (MRD) determined by classic polymerase chain reaction (PCR) methods is a powerful outcome predictor in mantle cell lymphoma (MCL). Nevertheless, some technical pitfalls can reduce the rate...
18.
Ferrante M, Furlan D, Zibellini S, Borriero M, Candido C, Sahnane N, et al.
Diagnostics (Basel)
. 2021 Apr;
11(5).
PMID: 33926007
In IgM monoclonal gammopathies MYD88 is a prognostic and predictive biomarker of therapy response. MYD88 detection is mainly performed by allele-specific quantitative PCR (ASqPCR), however recently, droplet digital PCR (ddPCR)...
19.
Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, et al.
Hematol Oncol
. 2021 Mar;
39(3):293-303.
PMID: 33742718
Minimal residual disease (MRD) monitoring by PCR methods is a strong and standardized predictor of clinical outcome in mantle cell lymphoma (MCL) and follicular lymphoma (FL). However, about 20% of...
20.
Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D, et al.
Ann Hematol
. 2021 Jan;
100(2):437-443.
PMID: 33392702
We analyzed variations in terms of chromosomal abnormalities (CA) by fluorescence in situ hybridization (FISH) analysis on purified bone marrow plasma cells throughout the progression from monoclonal gammopathy of undetermined...